Patent ID: 9669009
Date: 2017-06-06
CPC Classifications: A61K

Claim:
1. A method of treating a disease, condition or disorder that is therapeutically responsive to levetiracetam comprising orally administering one or more times daily to a subject in need thereof a rapidly dispersible solid dosage form comprising levetiracetam in a bound porous matrix that disperses in about 15 sec or less in a volume of about 15 ml or less of water or saliva, wherein the dosage form provides a Cmax within the ranges listed below when respective doses of levetiracetam are administered to the subject in the fasting state: wherein the bound porous matrix comprises 50-80% wt of levetiracetam (LEV), 3-35% wt of at least one disintegrant, and 0.5-20% wt of at least one binder wherein the matrix has a hardness of at least 2 kp.